Membranous Glomerulonephritis

This is another type of kidney disease affecting the filters in your kidneys. It happens when proteins build up on the outer side of the kidney's filtering units. This can lead to kidney damage over time.

Condition

What people with Membranous Glomerulonephritis report

Every report comes from a Lived member, sent anonymously.

Have you tried Rituximab for Membranous Glomerulonephritis?

NameHow it went

About Membranous Glomerulonephritis

What It Is

Membranous glomerulonephritis, more often called membranous nephropathy, is a kidney disease in which the kidney's filters leak large amounts of protein into the urine. Each kidney contains about a million tiny filtering units called glomeruli. In membranous nephropathy, immune deposits build up along the filter wall (the glomerular basement membrane), the wall thickens, and protein that should stay in the blood slips through. That protein loss is what people notice. Swelling (edema) builds gradually, along with foamy urine, tiredness, poor appetite and weight gain from retained fluid. Many people develop nephrotic syndrome, a combination of heavy protein in the urine, low protein in the blood, high cholesterol and swelling. Membranous nephropathy is one of the most common causes of nephrotic syndrome in adults. It matters for two reasons: the protein leak raises the risk of blood clots and infections, and in some people kidney function declines over years.

Causes & Risk Factors

In about 80 percent of people, membranous nephropathy is a primary disease: an autoimmune condition limited to the kidneys. The immune system makes antibodies against a protein on the cells that line the kidney filters. In roughly three out of four people with the primary form, the target is a protein called the phospholipase A2 receptor (PLA2R), and researchers have identified more than a dozen other targets. Why the immune system starts doing this is not known, and nothing a person did is known to cause it. In the remaining cases the disease is secondary, meaning it is linked to another condition. Recognized associations include infections such as hepatitis B, hepatitis C and syphilis; autoimmune diseases, especially lupus; some cancers, particularly solid tumors such as lung and colon cancer; and certain medicines and exposures, including nonsteroidal anti-inflammatory drugs (NSAIDs, such as ibuprofen), penicillamine, mercury and some skin-lightening creams. Finding a secondary cause matters because care then centers on treating or removing it. The disease can begin at any age, but it is most often diagnosed in middle-aged adults and is uncommon in children.

How It's Diagnosed

Diagnosis usually starts with a urine test that shows a large amount of protein. The amount is measured by collecting urine over 24 hours or, more often, by comparing protein with creatinine in a single sample (a protein-to-creatinine ratio). Losing 3.5 grams or more of protein a day is called nephrotic-range protein loss. Blood tests check albumin, the main protein in blood, where a level below about 3.0 grams per deciliter signals significant loss, along with cholesterol and kidney function. Kidney function is reported as an estimated glomerular filtration rate (eGFR), calculated from a creatinine blood test. An eGFR of 60 or above is generally adequate in a younger adult, although eGFR naturally falls with age. Many people still have normal or near-normal eGFR when first diagnosed. A kidney biopsy, in which a thin needle removes a small sample of kidney tissue for examination under a microscope, has traditionally confirmed the diagnosis by showing the characteristic immune deposits. A blood test for anti-PLA2R antibodies has changed this. It is positive in most people with primary membranous nephropathy and almost never positive in people without it. For someone with nephrotic syndrome and a positive test, international kidney guidelines say a biopsy is not required, although one may still be advised in some situations, such as reduced kidney function. A negative antibody test does not rule the disease out, and a biopsy is then usually needed. Because the disease can be secondary, everyone diagnosed should be checked for associated conditions, whatever the antibody result. This typically includes blood tests for hepatitis B, hepatitis C and HIV, tests for lupus, a review of medicines and supplements, and age-appropriate cancer screening, sometimes with a chest X-ray or CT scan.

Treatment Options

Treatment has two layers: supportive care for everyone, and immune-suppressing medicine for people whose disease is likely to get worse. In secondary membranous nephropathy, treating the underlying condition, such as hepatitis B or a cancer, or stopping a responsible medicine is the central step. Supportive care aims to reduce protein leakage, ease swelling and prevent complications. An angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB), blood pressure medicines that also lower pressure inside the kidney filters, reduces the amount of protein lost. Diuretics (water pills) and a lower-salt diet help with swelling, and a statin may be used for high cholesterol. Because heavy protein loss makes blood more likely to clot, some people, particularly those with very low albumin, are advised to take a blood thinner. That decision weighs the risk of a clot against the risk of bleeding. Many people with primary membranous nephropathy improve on their own, so immune treatment is not automatic. People with protein loss below the nephrotic range, normal albumin and an eGFR above 60 usually do not need it. For others with stable kidney function, guidelines generally suggest supportive care and close monitoring for about six months first, moving sooner when protein loss is very heavy, antibody levels are high, kidney function is falling, or a serious complication such as a clot has occurred. When immune treatment is needed, the choice depends on how high the risk is. Rituximab (Rituxan or a biosimilar) is an antibody given by intravenous infusion that removes the B cells making the harmful antibodies. It is widely used for moderate- to high-risk disease, and about 60 to 80 percent of people respond, though it is used off-label for this condition in the United States and its long-term protection against kidney failure is less proven. Calcineurin inhibitors (tacrolimus or cyclosporine), daily pills that dampen immune activity, can bring protein loss down, but relapse is common when they are stopped, so they suit moderate risk or are combined with rituximab. Their blood levels and kidney effects need regular checks. For the highest-risk disease, especially when kidney function is already falling, a six-month course alternating cyclophosphamide, a powerful chemotherapy-type immune suppressant, with corticosteroids has the clearest evidence for preventing kidney failure. It also has the most serious side effects, including infections, reduced fertility and a higher cancer risk at larger total doses, so it is reserved for the people who need it most. If the disease does lead to kidney failure, dialysis or a kidney transplant takes over the kidneys' work.

What to Expect

Membranous nephropathy usually unfolds slowly, over years rather than weeks. Among people with nephrotic syndrome, roughly a third go into remission on their own, about a third keep some protein leakage, and about a third eventually progress to kidney failure. People whose protein loss stays below the nephrotic range and whose kidney function is normal generally do well, though some later develop heavier protein loss, so follow-up still matters. Risk-based treatment aims to move more people into remission and away from kidney failure. Follow-up is regular and test-driven: urine protein, blood albumin, kidney function and, for people with anti-PLA2R antibodies, repeat antibody levels every few months. Falling antibody levels usually signal that remission is coming, often months before the urine improves, while antibodies that reappear can warn of a relapse. Responses to treatment take months, and relapses can happen after a period of remission and can be treated again. Day to day, the main burdens are swelling and tiredness while protein loss is heavy, limiting salt, keeping track of several medicines, and frequent lab visits. People on immune-suppressing treatment are more prone to infections during and after it. For those who reach kidney failure, a kidney transplant is generally the best option, although membranous nephropathy often returns in the new kidney and is watched closely afterward.

When to Seek Help

See a clinician if you have swelling, foamy urine or unexplained weight gain that persists, especially if a urine test has already shown protein. If you have membranous nephropathy, contact your care team when swelling or foamy urine returns or worsens, when you are passing much less urine than usual, or when you develop a fever or other signs of infection during immune-suppressing treatment. Contact your care team right away if one leg becomes newly painful, swollen, warm or red, which can signal a blood clot. Sudden shortness of breath, chest pain that worsens with a deep breath, or coughing up blood can mean a clot has reached the lungs and needs emergency care immediately.

Questions to Ask Your Doctor

  1. 1.Is my membranous nephropathy primary, or could it be linked to an infection, medicine or cancer that we should look for?
  2. 2.Based on my protein level, albumin, kidney function and antibody results, how likely am I to improve without immune treatment?
  3. 3.If I need immune treatment, how do rituximab, calcineurin inhibitors and cyclophosphamide compare for me, including infection risk and effects on fertility?
  4. 4.Should I be taking a blood thinner, and which signs of a clot should I watch for?
  5. 5.How often will we check my urine, blood tests and PLA2R antibodies, and what results would change the plan?

Last reviewed • Oct 2026

Educational content, not medical advice.